Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer

Journal of the National Cancer Institute

Volumn 95, Issue 15, 2003, Pages 1118-1127

  Reck, Martin ^a   von Pawel, Joachim ^b   Macha, Hans Nicolas ^c   Kaukel, Eckhard ^d   Deppermann, Karl Matthias ^e   Bonnet, Reiner ^f   Ulm, Kurt ^g   Hessler, Sybill ^h   Gatzemeier, Ulrich ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^c LUNGENKLINIK HEMER   (Germany)

^d Asklepios Klinik Harburg   (Germany)

^e Fachkrankenhaus fur Lungenheilkunde   (Germany)

^f ZENTRALKLINIK BAD BERKA   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CIMETIDINE; CISPLATIN; CLEMASTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOFOS; ETOPOSIDE; PACLITAXEL; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; ANALYSIS OF VARIANCE; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEMATOLOGIC DISEASE; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SMALL CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PATIENT SELECTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0041507037     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg017     Document Type: Article

References (62)

1. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC Sci Publ 1993;121.
2. Matthews MJ, Gordon PR. Morphology of pulmonary and pleural malignancies. In: Straus MJ, editor. Lung cancer: clinical diagnosis and treatment. New York (NY): Grune & Stratton; 1977. p. 49-69.
3. Devesa SS, Shaw GL, Blot WJ. Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev 1991;1:29-34.
4. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3. 1973;4:31-42.
5. Aisner J, Alberto P, Bitran J, Comis R, Daniels J, Hansen H, et al. Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 1983;67:37-43.
6. Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988;15:278-99.
7. Johnson DH, Einhorn LH, Birch R, Vollmer R, Perez C, Krauss S. et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987;5:1731-8.
8. Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol 2003; 30:9-25.
9. Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, et al. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J Clin Oncol 1987;5:1880-9.
10. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-9.
11. Raghavan D, Bishop JF, Kefford RF, Zalcberg J, Stuart-Harris R, Morstyn G, et al. Carboplatin combination chemotherapy regimens for undifferentiated small cell lung cancer. In: Bunn PA Jr, Canetta R, Ozols RF, Rosencweig M, editors. Carboplatin (JM-8): current perspectives and future directions. Philadelphia (PA): W. B. Saunders; 1990. p. 235-42.
12. Hoffmann W, Lohove F, Weidmann B, Migeos F, Seeber S. Carboplatin and etoposide combination chemotherapy in small cell lung carcinoma [abstract]. J Cancer Res Clin Oncol 1988;114 Suppl 5:180.
13. Evans WK, Eisenhauer E, Hughes P, Maroun JA, Ayoub J, Sheperd FA, et al. The National Cancer Institute of Canada experience with etoposide plus carboplatin in previously untreated patients with extensive small cell lung cancer. In: Bunn PA Jr, Canetta R, Ozols RF, Rosencweig M, editors. Carboplatin (JM-8): current perspectives and future directions. Philadelphia (PA): W. B. Saunders; 1990. p. 249-61.
14. Ellis PA, Talbot DC, Priest K, Jones AL, Smith IE. Dose intensification of carboplatin and etoposide as first-line combination chemotherapy in small cell lung cancer. Eur J Cancer 1995;31A:1888-9.
15. Katakami N, Takada M, Negoro S, Ota K, Fujita J, Furuse K, et al. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan. Cancer 1996;77: 63-70.
16. Luikart SD, Goutsou M, Mitchell ED, Van Echo DA, Modeas CR, Propert KJ, et al. Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A Report from the Cancer and Leukemia Group B. Am J Clin Oncol 1993;16:127-31.
17. Viren M, Liippo K, Ojala A, Helle L, Hinkka S, Huovinen R, et al. Carboplatin and etoposide in extensive small cell lung cancer. Acta Oncol 1994;33:921-4.
18. Pfeiffer P, Sorenson P, Rose C. Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer? Eur J Cancer 1995;31A:64-9.
19. Smith IE, Evans BD, Gore ME, Vincent MD, Repetto L, Yarnold JR, et al. Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 1987;5:185-9.
20. Bishop JF, Raghavan D, Stuart-Harris R, Morstyn G, Aroney R, Kefford R, et al. Carboplatin and VP-16 in previously untreated patients with small-cell lung cancer. J Clin Oncol 1987;5:1574-8.
21. Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L. Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer. J Clin Oncol 1992;10: 818-23.
22. Gatzemeier U, von Pawel J, Laumen R, Hossfeld DK, Neuhauss R, Reck M, et al. Carboplatin/etoposide/vincristine therapy in small cell lung cancer. Oncology 1992;49 Suppl 1:25-33.
23. Aisner J. Treatment of limited-disease small cell lung cancer. Semin Oncol 1992;19(6 Suppl 13):51-8.
24. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995;13: 1430-5.
25. Kirschling RJ, Jung SH, Jett JR. A phase II trial of taxol and G-CSF in previously untreated patients with extensive stage small cell lung cancer [abstract 1076]. Proc ASCO 1994;13:326.
26. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion J Clin Oncol 1994;12:2654-66.
27. Reek M, Jagos U, Kaukel E, Koschel G, von Pawel J, Wagener T, et al. Chemotherapy of limited stage small cell lung cancer with carboplatin, paclitaxel, and oral etoposide: a phase II trial [abstract 1887]. Proc ASCO 1999;18.
28. Deppermann KM, Serke M, Oehm C, Kurzeja A, Riedel U, Licheys HJ, et al. Paclitaxel and carboplatin in advanced small cell lung cancer: a phase II study [abstract 1860]. Proc ASCO 1999;18.
29. Thomas P, Castelnau O, Paillotin D, Lena H, Robinet G, Muir JF, et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie study. J Clin Oncol 2001;19:1320-5.
30. Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 1997;15:3464-70.
31. Bunn PA, Kelly K, Crowley J, Livingston RB, Gandara DR. Preliminary results from Southwest Oncology Group Trial 9705: a phase II trial of cisplatin, etoposide, and paclitaxel with G-CSF in untreated patients with extensive small cell lung cancer [abstract 1807]. Proc ASCO 1999;18.
32. Zarogoulidis K, Kontiakiotis T, Hatziapostoulou P, Tsianga E, Papakosta P, Goutsikas J, et al. Paclitaxel (P) in combination with carboplatin in the treatment of small cell lung cancer patients (a phase II study) [abstract 171]. Lung Cancer 2000;29(Suppl 1):53.
33. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32A:1135-41.
34. National Cancer Institute. Cancer Therapy Evaluation Programs (CTEP). Common toxicity criteria-Version 2.0. Bethesda (MD): Division of Cancer Treatment and Diagnosis, National Cancer Institute; 1999. Available at: http://ctep.cancer.gov/reporting/ctc.html [then click on "Common Terminology for Adverse Events v3.0 (CTCAE) (PDF). [Last accessed: June 10, 2003.]
35. Pocock SJ. Clinical trials: a practical approach. New York (NY): John Wiley & Sons; 1983.
36. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE. et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989:7:1748-56.
37. Reif S, Kingreen D, Kloft C, Grimm J, Siegert W, Schunack W, et al. Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients. Cancer Chemother Pharmacol 2001;48: 134-40.
38. Kaul S, Igwemezie LN, Stewart DJ, Fields SZ, Kosty M, Levithan N, et al. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. J Clin Oncol 1995;13:2835.
39. World Health Organization (WHO) Handbook for Reporting Results of Cancer Treatment. Geneva (Switzerland): WHO: 1979. Publ No. 48. Out-of-print publication is available online at: http://whqlibdoc.who.int/publications/9241700483.pdf. [Last accessed: June 19, 2003.]
40. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
41. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972;A135:185-98.
42. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982:38:29-41.
43. Cox DR. Regression models and life tables. J R Stat Soc 1972;B34: 187-220.
44. Berger U, Schafer J, Ulm K. Dynamic Cox modelling based on fractional polynomials: time-variations in gastric cancer prognosis. Stat Med 2003; 22:1163-80.
45. Hainsworth JD, Greco A. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. Semin Oncol 1999;26:60-6.
46. Wolf M, Havemann K. [Chemotherapy and combined chemoradiotherapy procedures in bronchial carcinoma] Internist (Berl) 1994;35:740-50.
47. Cottin V, Arpin D, Lasset C, Cordier JF, Brune J, Chauvin F, et al. Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. Ann Oncol 1999;10:809-15.
48. Stahel RA, Ginsberg R, Havemann K, Hirsch FR, Ihde DC, Jassem J, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989;5:119-26.
49. Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001;12:463-70.
50. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992;327:1618-24.
51. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-5.
52. Work E, Nielsen O, Bentzen SM, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. J Clin Oncol 1997;15:3030-7.
53. Perry MC, Eaton WL, Propert KJ, Ware JH, Zimmer B, Chahinian AP, et al. Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung. N Engl J Med 1987;316:912-8.
54. Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with one-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
55. Niell HB, Herndon JE, Miller AA, Watson DM, Sandler A, Kelly K, et al. Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC) [abstract 1169]. Proc ASCO 2002;21.
56. Canetta R, Bragman K, Smaldone L, Rozencweig M. Carboplatin: current status and future prospects. Cancer Treat Rev 1988;15 Suppl B:17-52.
57. Smith IE, Evans BD. Carboplatin as single agent and in combination in the treatment of small cell lung cancer. Cancer Treat Rev 1985;12:73-5.
58. Jacobs RH, Bitran JD, Deutsch M, Hoffmann PC, Sinkule J, Purl S, et al. Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma. Cancer Treat Rep 1987;71:311-2.
59. Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 1994;21(3 Suppl 6):23-30.
60. Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L. Phase II and III studies with carboplatin in small cell lung cancer. Semin Oncol 1992;19(1 Suppl 2):28-36.
61. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 1994;5:601-7.
62. Sobin LH, Wittekind C, editors. International Union Against Cancer (UICC): TNM classification of malignant tumours. 5th ed. Berlin (Germany): Springer; 1997.